Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients

Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson’s Disease, IRCSS San Camillo, Venice, Italy; ²Department for Parkinson’s Disease, Clinic San Pio X, Milan, ItalyAbstract: Immediate-release (IR) pramipexole...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Antonini A, Calandrella D
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://doaj.org/article/790fd554961049eb947f9d633128169f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:790fd554961049eb947f9d633128169f
record_format dspace
spelling oai:doaj.org-article:790fd554961049eb947f9d633128169f2021-12-02T06:49:28ZOnce-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients1176-63281178-2021https://doaj.org/article/790fd554961049eb947f9d633128169f2011-05-01T00:00:00Zhttp://www.dovepress.com/once-daily-pramipexole-for-the-treatment-of-early-and-advanced-idiopat-a7459https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson’s Disease, IRCSS San Camillo, Venice, Italy; ²Department for Parkinson’s Disease, Clinic San Pio X, Milan, ItalyAbstract: Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course.Keywords: advanced Parkinson’s disease, continuous drug delivery, early Parkinson’s disease, extended release, immediate release, pramipexoleAntonini ACalandrella DDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 297-302 (2011)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Antonini A
Calandrella D
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
description Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson’s Disease, IRCSS San Camillo, Venice, Italy; ²Department for Parkinson’s Disease, Clinic San Pio X, Milan, ItalyAbstract: Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course.Keywords: advanced Parkinson’s disease, continuous drug delivery, early Parkinson’s disease, extended release, immediate release, pramipexole
format article
author Antonini A
Calandrella D
author_facet Antonini A
Calandrella D
author_sort Antonini A
title Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
title_short Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
title_full Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
title_fullStr Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
title_full_unstemmed Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
title_sort once-daily pramipexole for the treatment of early and advanced idiopathic parkinson’s disease: implications for patients
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/790fd554961049eb947f9d633128169f
work_keys_str_mv AT antoninia oncedailypramipexoleforthetreatmentofearlyandadvancedidiopathicparkinsonamprsquosdiseaseimplicationsforpatients
AT calandrellad oncedailypramipexoleforthetreatmentofearlyandadvancedidiopathicparkinsonamprsquosdiseaseimplicationsforpatients
_version_ 1718399698047336448